RxDoctor Payments Data

Manuel Gonzalez, MD

Family Medicine · Miami, FLNPI 1780640607

Payments from drug & device makers

$12,262in general payments, 2019–2025

Across 549 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$2K
  • Amgen$2K
  • Novo Nordisk$2K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$705
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$12,241100%
  • Education$220%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,262 in reported general payments places this provider in the 90th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$42,008
Medicare patients
102
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide337$399,143
JardianceEmpagliflozin135$189,438
EliquisApixaban149$174,550
FarxigaDapagliflozin Propanediol112$107,348
Trelegy ElliptaFluticasone/Umeclidin/Vilanter79$92,324
MounjaroTirzepatide53$66,526
EntrestoSacubitril/Valsartan42$55,574
ZenpepLipase/Protease/Amylase29$52,199
XareltoRivaroxaban29$39,727
TrulicityDulaglutide17$24,455
Repatha SureclickEvolocumab23$21,509
LinzessLinaclotide15$16,997
Breztri AerosphereBudesonide/Glycopyr/Formoterol21$16,766
Repatha SyringeEvolocumab13$13,254
MyrbetriqMirabegron11$11,836

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,606$399,143337 claims
Boehringer IngelheimJardiance$705$189,438135 claims
PfizerEliquis$181$174,550149 claims
AstraZenecaFarxiga, Breztri Aerosphere, Crestor$1,806$133,222147 claims
GSKTrelegy Ellipta$2,098$92,32479 claims
Lilly USA, LLCMounjaro, Trulicity$1,102$90,98170 claims
NovartisEntresto$222$55,57442 claims
Aimmune Therapeutics, Inc.Zenpep$68$52,19929 claims
Johnson & JohnsonXarelto$113$39,72729 claims
AbbVieLinzess, Synthroid$129$23,05275 claims
Astellas Pharma US IncMyrbetriq$22$11,83611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →